Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

HC Wainwright & Co. repeats recommended purchase of Shattuck Labs (STTK)

Fintel will become HC Wainwright & Co. on April 20, 2023. repeated Shattuck Labs (NASDAQ:STTK) Coverage buy recommendation.

Analyst Price Forecast Suggests 504.71% Gains

Average 1 year as of April 6, 2023 price target $16.93 for Shattuck Labs. Predictions range from a low of $9.09 to a high of $29.40. The average price target represents a 504.71% increase from the latest reported closing price of $2.80.

see us corporate leaderboard Maximum price target upwards.

Shattuck Labs’ projected annual revenue is $0MM, down 100.00%. Projected annual non-GAAP EPS -$2.54.

What are other shareholders doing?

FNCMX – Fidelity Nasdaq Composite Index Fund It holds 21,000 shares representing a 0.05% ownership interest in the company. No change from the previous quarter.

Variable Insurance Product Fund IV – Healthcare Portfolio Early Class It owns 37,000 shares representing a 0.09% ownership interest in the company. No change from the previous quarter.

FSPHX – Healthcare Portfolio It holds 1,163,000 shares representing a 2.74% ownership interest in the company. No change from the previous quarter.

DFVEX – US Vector Equity Portfolio – Institutional Class It owns 11,000 shares representing a 0.02% ownership interest in the company. No change from the previous quarter.

FSMAX – Fidelity Extended Market Index Fund It holds 177,000 shares representing a 0.42% ownership interest in the company. In previous filings, the company reported that it owned 144,000 of his shares. will increase 18.37%.office decreased Portfolio allocation at STTK increased by 14.12% last quarter.

What is Fund Sentiment?

there is 100 funds or institutions reporting positions At the Shattuck Institute. This is his 24 owners or a decrease of 19.35% in the previous quarter.Portfolio average weight of all funds STTK dedicated was 0.05%, an increase of 24.51%. The total number of shares owned by institutional investors fell by 4.46% to 20,702 thousand shares in the last three months. STTK/Shattuck Labs Inc put/call ratio of put/call ratio has an STTK of 0.05, indicating a bullish outlook.

Background Information on Shattuck Labs
(This description is provided by the company.)

Shattuck Labs, Inc. operates as a clinical-stage biotechnology company. The Company is focused on developing a new class of biological medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in Texas.

See all Shattuck Labs Submissions to regulatory authorities.

This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

Summarize this content to 100 words

Fintel will become HC Wainwright & Co. on April 20, 2023. repeated Shattuck Labs (NASDAQ:STTK) Coverage buy recommendation. Analyst Price Forecast Suggests 504.71% Gains Average 1 year as of April 6, 2023 price target $16.93 for Shattuck Labs. Predictions range from a low of $9.09 to a high of $29.40. The average price target represents a 504.71% increase from the latest reported closing price of $2.80. see us corporate leaderboard Maximum price target upwards. Shattuck Labs’ projected annual revenue is $0MM, down 100.00%. Projected annual non-GAAP EPS -$2.54.

What are other shareholders doing? FNCMX – Fidelity Nasdaq Composite Index Fund It holds 21,000 shares representing a 0.05% ownership interest in the company. No change from the previous quarter. Variable Insurance Product Fund IV – Healthcare Portfolio Early Class It owns 37,000 shares representing a 0.09% ownership interest in the company. No change from the previous quarter. FSPHX – Healthcare Portfolio It holds 1,163,000 shares representing a 2.74% ownership interest in the company. No change from the previous quarter. DFVEX – US Vector Equity Portfolio – Institutional Class It owns 11,000 shares representing a 0.02% ownership interest in the company. No change from the previous quarter. FSMAX – Fidelity Extended Market Index Fund It holds 177,000 shares representing a 0.42% ownership interest in the company. In previous filings, the company reported that it owned 144,000 of his shares. will increase 18.37%.office decreased Portfolio allocation at STTK increased by 14.12% last quarter. What is Fund Sentiment? there is 100 funds or institutions reporting positions At the Shattuck Institute. This is his 24 owners or a decrease of 19.35% in the previous quarter.Portfolio average weight of all funds STTK dedicated was 0.05%, an increase of 24.51%. The total number of shares owned by institutional investors fell by 4.46% to 20,702 thousand shares in the last three months. of put/call ratio has an STTK of 0.05, indicating a bullish outlook.

Background Information on Shattuck Labs(This description is provided by the company.) Shattuck Labs, Inc. operates as a clinical-stage biotechnology company. The Company is focused on developing a new class of biological medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in Texas. See all Shattuck Labs Submissions to regulatory authorities. This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-shattuck-labs-sttk-buy-recommendation HC Wainwright & Co. repeats recommended purchase of Shattuck Labs (STTK)

Back to top button